Sinovac to Present at Inaugural China Healthcare Investment Conference

BEIJING, March 23 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. , a leading China-based vaccine manufacturer, announced today that Mr. Weidong Yin, Chairman, President and CEO of Sinovac, is scheduled to partake in Track One: Pharmaceuticals and Biotech at the Inaugural China Healthcare Investment Conference on March 30, 2010. Sinovac is one of five publicly traded life sciences companies that will make a 20-minute company presentation starting at 9:35 a.m. China Standard Time (CST). Mr. Yin will participate subsequently in the presenting company panel that commences at 10:35 a.m. CST. The conference will be held on March 29-31 at the Grand Hyatt in Shanghai, China.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

About China Healthcare Investment Conference

The China Healthcare Investment Conference is the premier event of its kind in China. As the leading event of the year focusing on rapidly-growing Chinese healthcare companies, the Conference will be a great opportunity to meet with emerging companies, industry leaders, key government officials and investors from China and the West.

Recognizing that the healthcare reform and industry growth is spurring a new wave of emerging Chinese healthcare companies, a group of sponsors including KPCB, Fidelity Asia Ventures, Vivo Ventures and Piper Jaffray are leading the efforts to organize this prestigious annual event. The group is committed to turn this meeting into a powerful platform to promote and nurture investment in healthcare in China, and further develop the industry.

For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: [phone] x9871 Fax: [phone] Email: [e-mail] Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: [phone] Email: [e-mail] [e-mail] Media: Janine McCargo The Ruth Group Tel: [phone] Email: [e-mail]

Sinovac Biotech Ltd.

CONTACT: Helen G. Yang of Sinovac Biotech Ltd., [phone] x9871,
fax, [phone], or [e-mail]; Investors: Amy Glynn/Stephanie
Carrington of The Ruth Group, [phone]/7017, [e-mail],
or [e-mail]; Media: Janine McCargo of The Ruth Group,
[phone], or [e-mail]